Author： Ferry Sven Holm Stig Stenlund Hans Lundholm Rolf Monsen Tor
Publisher： Informa Healthcare
ISSN： 0281-3432
Source： Scandinavian Journal of Primary Health Care, Vol.25, Iss.1, 2007-01, pp. : 49-57
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Objective. To analyse associations between symptoms and bacteriuria in uncomplicated lower urinary tract infection in women (LUTIW) and to evaluate outcome of therapy with three different regimens of pivmecillinam or placebo. Design. Prospective, multicentre, randomized, double-blind, and placebo-controlled therapy study. Symptoms registered at inclusion, during therapy and at follow-up visits after 8-10 and 35-49 days. Significant bacteriuria defined according to current European guidelines. Setting. A total of 18 primary healthcare centres in northern Sweden. Subjects. Women aged 18 years and above with symptoms of urgency, dysuria, supra pubic or loin pain. Main outcome measures. Symptoms and bacteriuria at inclusion and course of symptoms, bacteriuria, and their combinations during and post-therapy. Results. At inclusion, no associations or significant differences were found between symptom scores and bacteriuria, bacterial counts, or species. The 884 patients (77%) with significant bacteriuria were followed up. All pivmecillinam therapies were superior to placebo (p < 0.001). From day six until first follow-up, the mean values of all symptoms were higher and the bacteriological cure was lower at first follow-up in the three days (84%) compared with the seven days regimens (93-94%, p < 0.001). At final follow-up clinical cure was similar in all pivmecillinam regimens (65-72%) as was bacteriological cure (83-89%). Pivmecillinam had few low to mild adverse reactions, comparable to placebo. Conclusions. Symptoms are not conclusive for diagnosis of LUTIW. Pivmecillinam therapies are superior to placebo and seven days regimens are more efficient than three days. Pivmecillinam 200 mg×2×7 days is recommended as a first-line therapy for LUTIW.
Related content
By Ferry Sven Holm Stig Stenlund Hans Lundholm Rolf Monsen Tor
Scandinavian Journal of Infectious Diseases, Vol. 36, Iss. 4, 2004-04 ,pp. :
Access to resources
Recommend
By Nicolle L. E. Madsen K. S. Debeeck G. O. Blochlinger E. Borrild N. Bru J. P. Ckinnon C. M O'Doherty B. Spiegel W. Van Balen F. A. M. Enday P. M
Scandinavian Journal of Infectious Diseases, Vol. 34, Iss. 7, 2002-07 ,pp. :
By Baerheim Anders Digranes Asbjørn Hunskaar Steinar
Scandinavian Journal of Primary Health Care, Vol. 17, Iss. 3, 1999-10 ,pp. :